An NDIS participant with a chronic condition can enjoy a taxpayer-supported cruise with their support team. Does it make sense that, at the same time, they could be denied funded access to medicine or other health technology that could significantly improve their health and quality of life? Where is the equity and opportunity cost in that?
Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?
April 23, 2024 Latest NewsBioPharmaCommentLatest Video
New Stories
-
The Week in Review Podcast - 3 May
May 3, 2024 - - Podcast -
New data shows significant increase in the number of pharmacies supplying naloxone
May 3, 2024 - - Latest News -
CSL Seqirus secures local rights to new adrenaline nasal spray
May 3, 2024 - - Latest News -
Industry applauds funding commitment for National One Stop Shop for clinical trials
May 3, 2024 - - Latest News -
Access should not be redefined as including access via a clinical trial
May 3, 2024 - - Latest News -
Another reform process fails - how many times does this need to happen?
May 2, 2024 - - Latest News -
New coalition established to advocate for action on radiation therapy
May 2, 2024 - - Latest News